에서 실시간으로 운영 중이에요! 자세히 알아보기

Journey Medical

DERM

시가총액 US$1.4억

4.96 USD

-0.17

3.31%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-3.31%

5일

-22.5%

1개월

-31.96%

3개월

-30.24%

6개월

-4.06%

연초 이후

-33.42%

1년

-32.97%

5년

-47.79%

10년

-47.79%

소개: Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

직원 수: 58

건강관리 의약품 제조업체 - 전문의약품 및 제네릭

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 40%

중립 60%

부정적 0%

Journey Medical: A Small Pharma With A Large Growth Opportunity

Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years.

Journey Medical: A Small Pharma With A Large Growth Opportunity

Journey Medical Corporation to Participate in September 2026 Investor Conferences

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Zacks Investment Research

ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?

Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.

ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration are expected to improve further.

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

Journey Medical Q2 Earnings Call Highlights

Journey Medical NASDAQ: DERM reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement.

Journey Medical Q2 Earnings Call Highlights

Zacks Investment Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026.

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.